Postmenopausal Osteoporosis: A Review of Latest Guidelines.
American Association of Clinical Endocrinolo-gists
American College of Endocrinology
Dual-energy X-ray absorptiometry
FRAX
Fragility fracture
Osteopenia
Postmenopausal osteoporosis
Treatment guidelines
Journal
Endocrinology and metabolism clinics of North America
ISSN: 1558-4410
Titre abrégé: Endocrinol Metab Clin North Am
Pays: United States
ID NLM: 8800104
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
24
10
2024
Statut:
ppublish
Résumé
Osteoporosis is characterized by increased bone turnover and reduced bone mass, leading to skeletal fragility and heightened fracture risk. It is a growing public health concern with expectations for a continued significant rise of fractures by 50% in 2030. Diagnosis is typically based on body mineral density with a T-score of -2.5 or lower indicating osteoporosis. Treatment duration varies, and is determined by careful monitoring of fracture risk and timing for potential drug holidays. Emerging therapies and ongoing research continue to evolve the landscape of osteoporosis management, aiming to reduce fracture risk and improve patient outcomes.
Identifiants
pubmed: 39448132
pii: S0889-8529(24)00065-3
doi: 10.1016/j.ecl.2024.08.008
pii:
doi:
Substances chimiques
Bone Density Conservation Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-512Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The author has nothing to disclose.